Nath Bio-Genes (India) Limited has informed the Exchange about General Updates

Mgmt Guided Margin PressureInvestor Communications View source PDF

NATHBIOGEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-5.4%1-day move

₹188.00

prior close

₹180.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.4-3.9-3.7-4.0-5.4-7.4-8.5-11.2-13.8-14.8-9.0-10.6-10.2—

Up moveDown movePending

AI summary

Nath Bio-Genes reported FY26 revenue of ₹4,316 Mn, up 19% YoY driven by strong volume growth in Cotton Bt (22%), Paddy (25%), and Maize (54%). However, margins contracted significantly — gross margin fell to 56% from 63% and EBITDA margin dropped to 12% from 14% in FY25. PAT declined 8% to ₹384 Mn due to higher finance costs (up 38% to ₹133 Mn) and increased tax expense (up 135%). The company achieved its first ₹15 Crore revenue from Uzbekistan, marking international expansion. Finance costs surged while net debt more than doubled to ₹510 Mn vs ₹235 Mn in FY25.

Likely market impact

Strong topline growth was offset by margin compression and rising debt levels, signaling operational pressure despite volume growth. Shareholders may face diluted profitability even as revenue scales up.